Source link : https://www.newshealth.biz/health-news/cabozantinib-improves-pfs-for-advanced-neuroendocrine-tumors/
Cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors (NETs), according to final results from the phase III CABINET trial. In the group of 203 patients with extrapancreatic NETs, the median PFS was 8.4 months with cabozantinib compared with 3.9 months with placebo (HR 0.38, […]
Author : News Health
Publish date : 2024-09-17 18:22:10
Copyright for syndicated content belongs to the linked Source.
Categories